Efficacy of Intranasal Corticosteroid (Fluticasone) on Adenotonsillar Hypertrophy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210228050524N1

Enrollment

Registered

2021-05-08

Start date

2021-03-17

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy of Intranasal Corticosteroid (Fluticasone) on Adenotonsillar Hypertrophy.

Interventions

Intervention group: In this study, patients aged 4 to 10 years with the described symptoms are analyzed. They take Fluticasone nasal spray for two weeks. We do not have a control group .According to a

Eligibility

Sex/Gender

All

Age

4 Years to 10 Years

Inclusion criteria

Inclusion criteria: Children 4 to 10 Years Old With Adenotonsillar Hypertrophy Existence Of Snoring Existence Of Enlarged tonsils in clinical examination Existence Of Nasal congestion Existence Of Rhinorrhea

Exclusion criteria

Exclusion criteria: Existence Of Anatomical Abnormalities Existence Of Neuromuscular Disease Existence Of Upper Respiratory Tract Infections Existence Of Allergic Rhinitis Existence Of Recurrent Tonsillitis

Design outcomes

Primary

Measure	Time frame
Adenotonsillar Hypertrophy in clinical examination and symptoms of nasal congestion, snoring, rhinorrhea. Timepoint: Two Weeks. Method of measurement: Clinically and according to the opinion of the ENT Specialist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hamed Hatefi

Yazd University of Medical Sciences

drh_hatefi@yahoo.com+98 35 3138 0015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026